Please assess the completion status of the following clinical trial:

Trial Title: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Volunteer to participate in this clinical study; Completely understand and know this study as well as sign the informed consent form (ICF);~2. Age ≥ 18 years and ≤ 80 years when ICF is signed;~3. Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\>) 2 centimeters (cm) by standard local assessment technique; Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4, any N, M0); HER2-positive breast cancer confirmed by immunohistochemistry or HER2 gene amplification by in situ hybridization; Estrogen receptor and Progesterone receptor negative.~4. Eastern Cooperative Oncology Group Performance Status equal to or less than (\<=) 1.~5. Baseline left ventricular ejection fracture \>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan~Exclusion Criteria:~1. Stage IV metastatic breast cancer;~2. Inflammatory breast cancer;~3. Previous anti-cancer therapy or radiotherapy for any malignancy;~4. History of malignancies other than colorectal cancer within 5 years prior to randomization, excluding cutaneous basal cell carcinoma, cervical carcinoma in situ, and thyroid papillary adenocarcinoma of non-melanoma after radical treatment;~5. Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy;~6. Major surgical procedure within 4 weeks prior to randomization or from which the participant has not fully recovered;~7. Serious cardiac illness or medical condition;~8. Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness;~9. Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol;~10. Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Plus（+） QL1209 + Docetaxel (Type: EXPERIMENTAL): Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
- Trastuzumab Plus（+） Pertuzumab + Docetaxel (Type: ACTIVE_COMPARATOR): Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).